A consortium including Waverise Investments, ChrysCapital Fund X, and Two Infinity Partners has launched an open offer to acquire equity shares of Novartis India Limited, according to a regulatory filing. The transaction signals significant private equity consolidation within India’s pharmaceutical sector, offering a strategic transition for the company's public shareholding structure.
MUMBAI — A powerful financial consortium consisting of WaveRise Investments, ChrysCapital Fund X, and Two Infinity Partners has initiated a mandatory open offer to acquire up to 26 percent of the public equity shares of Novartis India Limited. According to official regulatory filings submitted to Indian exchange networks, the joint acquirers have fixed the buying price at 860.64 Indian rupees ($9.62) per offer share.
The transaction marks a major turning point in the domestic pharmaceutical industry, shifting control of a prominent multinational healthcare platform into the hands of homegrown private equity operators.
Financial Framework of the Takeover Deal
The regulatory framework governing the transaction outlines a multi-tiered buyout strategy structured around strict regulatory compliance. The mandatory open offer was officially triggered under Securities and Exchange Board of India (SEBI) Substantial Acquisition of Shares and Takeovers regulations following a definitive share purchase agreement with the Swiss parent company, Novartis AG.
Under the underlying agreement, Novartis AG has agreed to divest its entire 70.68 percent promoter stake—comprising 1,74,50,680 fully paid-up equity shares—to the consortium for a total consideration of approximately 1,445.89 crore Indian rupees.
To satisfy the statutory takeover thresholds, the acquirers have launched the subsequent public open offer to buy up to 64,19,608 outstanding equity shares of face value 5 Indian rupees each from minority public investors. If fully subscribed by market participants, the public portion of the acquisition will accumulate a total cash payout of 552.49 crore Indian rupees, lifting the consortium's potential ownership profile to an aggregate of 96.68 percent.
The investment group is structured via specific corporate entities:
WaveRise Investments Limited: A Mauritius-incorporated investment entity acting as the primary transaction vehicle.
ChrysCapital Fund X: The flagship multi-billion-dollar fund under ChrysCapital, one of India's largest and most active domestic private equity institutions.
Two Infinity Partners: A seasoned partnership firm collaborating on large-scale mid-market corporate buyouts.
Corporate Restructuring and Post-Deal Mandates
The formal exit of Basel-based parent firm Novartis AG follows an exhaustive strategic review of its local public assets initiated early last year. Company statements reveal that the parent entity intends to streamline its operations into a pure-play innovative medicines provider, adapting its international manufacturing and licensing footprint for sustainable long-term asset growth.
Crucially, the global firm will preserve its heavy institutional footprint in the country via its wholly owned subsidiary, Novartis Healthcare Private Limited, which houses its sprawling commercial drug development teams and corporate hubs in Hyderabad.
Stock exchange documents reveal clear post-acquisition operational targets:
Rebranding Directives: Under the definitive agreement, the target company must undergo a complete re-branding process to systematically remove all explicit references to the "Novartis" brand identity within 120 days of the closing window.
Listing Assurances: The consortium stated in its detailed public submission that it does not intend to delist the company from domestic exchanges, confirming it will take necessary statutory measures to align with SEBI's minimum 25 percent public float rule if the open offer results in an over-subscription.
Investor Sentiments and Market Reactions
For market investors and public shareholders, the open offer price of 860.64 Indian rupees represents a modest 3.64 percent premium over the initial closing price immediately preceding the announcement. However, domestic equity markets responded with significant enthusiasm, driving the target stock to hit its 20 percent upper circuit limits on the Bombay Stock Exchange (BSE) at 996.50 Indian rupees as traders adjusted to the structural change in management control.
Financial analysts project that under private equity direction, the legacy product catalog which includes popular wholesale medications spanning pain management, bone health, and anti-infective formulations will witness expanded distribution networks. ChrysCapital's existing healthcare portfolio includes major domestic formulation brands such as La Renon Healthcare and Intas Pharmaceuticals, offering immediate integration advantages.
Official Industry and Corporate Positions
The administrative parameters of the open offer have been compiled and verified by appointed merchant bankers managing the public tendering cycle.
"According to officials managing the transaction filings, the acquirers are fully capitalized to execute the entire cash payout commitments required under the takeover code," regulatory filings stated. "The transaction remains bound to standard closing procedures, with the consortium focusing on delivering long-term commercial backing to scale local pharmaceutical distribution pipelines."
Why It Matters
This landmark transition underscores a broader consolidation trend sweeping through emerging market pharmaceutical networks. As global drug pioneers shift their strategic focus toward complex oncology pipelines and highly targeted biologic agents, institutional private equity funds are aggressively capitalizing on cash-generating legacy brands, driving deeper localization of consumer healthcare access across regional markets.
Key Facts at a Glance
Target Stock: Novartis India Limited (BSE: NOIN.BO / NSE: NOVARTIND)
Offer Price: 860.64 Indian rupees per fully paid-up equity share.
Open Offer Size: Up to 64,19,608 equity shares, representing 26 percent of voting capital.
Promoter Stake Divestment: Novartis AG is selling its complete 70.68 percent holding for 1,445.89 crore Indian rupees.
Lead Financial Advisors: Axis Capital Limited is acting as the official manager to the public open offer.
Frequently Asked Questions
Why is Novartis AG selling its stake in Novartis India Limited?
The divestment follows a global strategic alignment initiated by Novartis AG to optimize its operational footprint and transition entirely into a pure-play innovative medicines provider.
What should public shareholders consider regarding the open offer price?
The open offer price is fixed at 860.64 Indian rupees per share. Shareholders can choose to tender their shares into the offer for guaranteed cash or hold their equity positions to remain invested under the new private equity management structure.
Will the company be delisted after the acquisition?
No. The acquiring consortium led by ChrysCapital has officially stated that they do not intend to delist the company from public stock exchanges and will comply with standard public float requirements.
Source: Securities and Exchange Board of India, BSE Limited, Novartis AG Investor Relations
